Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Blood (2022) 140 (Supplement 1): 2654–2655.

https://doi.org/10.1182/blood-2022-167119

Published: 2022

Journal Articles

The Easix Score Predicts Overall Survival and Late Relapse in Patients Undergoing Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation for Myeloid Disease

Chris Armstrong, Eibhlin Conneally, Catherine M Flynn, Nicola Gardiner, Hayley Foy-Stones, Aidan Kelly, Mairead Ni Chonghaile, Nina Orfali

Blood (2022) 140 (Supplement 1): 12900–12901.

https://doi.org/10.1182/blood-2022-166093

Published: 2022

Journal Articles

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Jose Valentín García Gutiérrez, MD PhD, Jerald P. Radich, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD PhD, Tamas Masszi, MD PhD Prof., Andrzej Hellmann, MD PhD, Jesper Stentoft, MD PhD, María Teresa Gomez Casares, MD PhD, Eibhlin Conneally, MB, PhD MRCP, MRCPath, Philipp D le Coutre, MD, Norbert Gattermann, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MD FRCPI, FRCPath, Paola Aimone, MD, Sai Li, MD PhD, Ksenia Titorenko, MS, David M. Ross, MD MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137388

Published: 2020

Journal Articles

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Karl Haslam, MPhil MBA, Niamh Appleby, FRCPath, Christopher Armstrong, MB MRCPI, Catherine M. Flynn, MD MRCP, FRCPath, Stephen Langabeer, PhD FRCPath, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2016) 128 (22): 2277.

https://doi.org/10.1182/blood.V128.22.2277.2277

Published: 2016

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Claire N. Harrison, Jean-Jacques Kiladjian, MD PhD, Florian H. Heidel, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, MD, Daniel B. Lipka, MD, Suddhasatta Acharyya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Susan Ide, PhD, Tracy Liu, Song Mu, PhD, Vincent Ribrag, MD

Blood (2015) 126 (23): 4060.

https://doi.org/10.1182/blood.V126.23.4060.4060

Published: 2015

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 711.

https://doi.org/10.1182/blood.V124.21.711.711

Published: 2014

Journal Articles

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Vincen t Ribrag, Claire N Harrison, DM, FRCP, FRCPath, Florian H Heidel, MD, Jean-Jacques Kiladjian, MD, PhD, Suddhasatta Acharyya, PhD, Song Mu, PhD, Tracy Liu, Denise Williams, MD, Francis J Giles, MB, MD, FRCPI, FRCPath, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Thomas Kindler, MD, Francesco Passamonti, MD, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 4045.

https://doi.org/10.1182/blood.V122.21.4045.4045

Published: 2013

Journal Articles

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Michael E O'Dwyer, MD, FRCPI, FRCPath, Ronan Swords, MD, MRCPI, FRCPath, Francis Giles, MD FRCPI FRCPath, Mary Frances McMullin, MD, Philipp D. le Coutre, MD, Arnon Nagler, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Karine Egan, Brian Moulton, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD

Blood (2011) 118 (21): 3774.

https://doi.org/10.1182/blood.V118.21.3774.3774

Published: 2011

Journal Articles

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Ronan T Swords, MD, MRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Mary Frances McMullin, MD, Philipp le Coutre, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Brian Moulton, Karine Egan, Michael O'Dwyer, MD, FRCPath

Blood (2010) 116 (21): 3427.

https://doi.org/10.1182/blood.V116.21.3427.3427

Published: 2010

Journal Articles

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Michael C O'Dwyer, MD, FRCPI, FRCPath, Emma Kent, Michael Parker, BSc, MSc, CStat, CMath, Ronan T. Swords, M.D., Frank Giles, MD, MB, FRCPI, FRCPath, Philipp le Coutre, MD, Swaminathan Padmanabhan, MD, MBBS, Brian Moulton, Ph.D, Mary Frances McMullin, Stephen Langabeer, PhD, Karine Egan, Ph.D, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2009) 114 (22): 3294.

https://doi.org/10.1182/blood.V114.22.3294.3294

Published: 2009

Journal Articles

Mutation Mediated Resistance to the Tyrosine Kinase Inhibitors Imatinib, Dasatinib & Nilotinib in Philadelphia Positive Leukaemia

Lisa M O’ Connor, PhD, Stephen Langabeer, PhD, Shaun R. McCann, Eibhlin Conneally, MB, MRCP, MRCPath, PhD

Blood (2008) 112 (11): 4245.

https://doi.org/10.1182/blood.V112.11.4245.4245

Published: 2008

Journal Articles

BCR-ABL Kinase Domain Mutations & SNPs in Imatinib Resistant or Intolerant Chronic Myeloid Leukaemia Patients.

Lisa M. O’Connor, PhD, Stephen Langabeer, PhD, Shaun R. McCann, MD, Eibhlin Conneally, MD

Blood (2007) 110 (11): 2369.

https://doi.org/10.1182/blood.V110.11.2369.2369

Published: 2007

Journal Articles

Outcome of Sibling Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantations in Low-Grade B Cell Lymphoproliferative Disorders. A Single Centre Experience.

Ronan Desmond, Marianna David, Eibhlin Conneally, Paul Browne, Mairead Ni Conghaile, Shaun McCann, Elizabeth Vandenberghe

Blood (2007) 110 (11): 5059.

https://doi.org/10.1182/blood.V110.11.5059.5059

Published: 2007

Journal Articles

Imatinib Mesylate Treatment of Patients with Chronic Myeloid Leukaemia Relapsing Following Allogeneic Stem Cell Transplantation.

Eibhlin Conneally, MB, Ph. D, Peig Carroll, B.Sc, Michael Neat, M.Sc, Karl Haslam, M.Sc, Kathy Gately, Ph.D, Jacqui Ryan, M.SC, Mark Lawler, Ph.D, Shaun McCann, MB

Blood (2004) 104 (11): 4659.

https://doi.org/10.1182/blood.V104.11.4659.4659

Published: 2004

Journal Articles

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML

Shaun R. McCann, Kathy Gately, Eibhlin Conneally, Mark Lawler

Blood (2003) 101 (3): 1200.

https://doi.org/10.1182/blood-2002-09-2932

Published: 2003

Journal Articles

Modulation of p210 BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming

Yves Chalandon, Xiaoyan Jiang, Glen Hazlewood, Slade Loutet, Eibhlin Conneally, Allen Eaves, Connie Eaves

Blood (2002) 99 (9): 3197–3204.

https://doi.org/10.1182/blood.V99.9.3197

Published: 2002

NARROW

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

The Easix Score Predicts Overall Survival and Late Relapse in Patients Undergoing Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation for Myeloid Disease

Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR 4.5 : Results from ENESTfreedom

Impact of Somatic Mutations on Clinical Outcomes Following Flamsa-Bu Conditioning and Allogenic Stem Cell Transplantation in Patients with Poor-Risk Myeloid Malignancies

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Mutation Mediated Resistance to the Tyrosine Kinase Inhibitors Imatinib, Dasatinib & Nilotinib in Philadelphia Positive Leukaemia

BCR-ABL Kinase Domain Mutations & SNPs in Imatinib Resistant or Intolerant Chronic Myeloid Leukaemia Patients.

Outcome of Sibling Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantations in Low-Grade B Cell Lymphoproliferative Disorders. A Single Centre Experience.

Imatinib Mesylate Treatment of Patients with Chronic Myeloid Leukaemia Relapsing Following Allogeneic Stem Cell Transplantation.

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML

Modulation of p210 BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only